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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.025Although various lines of evidence suggest that oxidative stress plays a role in human prostate cancer
initiation and progression, there is a paucity of direct evidence for its role in tumor initiation. To begin
to address this issue, we developed a novel tumorigenesis model by reducing the expression of multiple
selenoproteins (SPs) in mouse prostatic epithelium. This was accomplished via the prostate-speciﬁc
deletion of Trsp, a gene that encodes a transfer RNA (Sec tRNA) required for the insertion of seleno-
cysteine residues into SPs during their translation. By 6 weeks of age, Trsp-deﬁcient mice exhibited
widespread prostatic intraepithelial neoplasia lesions in all prostatic lobes, which then progressed to
high-grade dysplasia and microinvasive carcinoma by 24 weeks. In contrast to other murine prostate
cancer models, Trsp-deﬁcient mice required neither the deletion of a tumor suppressor nor the trans-
genic introduction of an oncogene for prostatic intraepithelial neoplasia lesion development. In
keeping with the antioxidant functions of several SPs, we found increases in lipid peroxidation markers
in Trsp-deﬁcient epithelial cells. This novel model of prostate neoplasia provides evidence for the ex-
istence of a selenoprotein or selenoproteins capable of acting as a tumor suppressor in the murine
prostate. (Am J Pathol 2014, 184: 871e877; http://dx.doi.org/10.1016/j.ajpath.2013.11.025)Supported by a grant from the Alberta Cancer Foundation, Alberta
Innovates-Health Solutions (F.R.J.). F.R.J. was the recipient of a Canada
Research Chairs award.
Disclosures: None declared.Prostate cancer is the second most common cancer in men
after skin cancer in the United States, and it has been esti-
mated that approximately 242,000 men were diagnosed with
this disease, and that approximately 28,000 men died of this
malignancy in 2012 [Surveillance, Epidemiology, and End
Results (SEER) Program; http://seer.cancer.gov/statfacts/
html/prost.html]. Adequate selenium (Se) levels have long
been proposed as one of the factors preventing the devel-
opment of various types of malignancy (reviewed in Brigelius-
Flohe1 and Davis et al2) including prostate cancer. Se is an
essential dietary micronutrient that is found in association with
various organic molecules, including the 21st amino acid,
selenocysteine (Sec).3 The latter molecule is essential for the
normal function of the selenoprotein (SP) family of proteins.
Indeed, SP synthesis requires that Sec residues be inserted into
the growing polypeptide chains opposite speciﬁc UGA codonsstigative Pathology.
.that are present within the coding regions of SP mRNAs.4
Although in the eukaryotic nucleus, UGA ordinarily spec-
iﬁes a translational stop, in the case of the selenoprotein gene
coding regions, the UGA codon is recognized by a speciﬁc
transfer RNA, Sec tRNA (designated Sec tRNA[Ser]Sec), that is
encoded by the Trsp gene. Recognition of the appropriate
UGA codon(s) in SPs is enabled by a group of proteins that
recognize a Sec insertion sequence that is located within the
30 untranslated regions of SP mRNAs.5
There are 25 human and 24 murine SP genes,6 approxi-
mately one-third of which function as antioxidants. This
Luchman et alfamily includes the important glutathione peroxidases (GPx)
1 through 47 that are responsible for protecting cells against
reactive oxygen species (ROS)-mediated and reactive ni-
trogen speciesemediated damage to cellular macromole-
cules.6 Other members of the SP family, such as the
thioredoxin reductases, are critical regulators of intracellular
redox potential, and thus regulate the activities of redox-
sensitive signal transduction molecules and transcription
factors.7,8
Although the function of many SPs is still unknown,
other than that they may participate in antioxidant and
anabolic processes, the SPs that are most likely to be rele-
vant to an increased cancer risk are those of the GPx family,
the 15-kDa selenoprotein (Sep15), and the thioredoxin re-
ductases, previously implicated in various cancers,
including prostate cancer (reviewed in Rayman9 and
Davis2). It has been proposed that SPs may exert protective
effects, not only against tumorigenesis, but also against
cancer progression and metastasis.10,11 There is evidence of
an association between Se and reductions in DNA damage
and oxidative stress, together with data showing an effect of
SP genotype on cancer risk, thus suggesting that alterations
in SP activity may have a role in tumorigenesis (reviewed in
Rayman9). To begin to study this possibility, SP levels were
reduced via the transgenic expression of a mutant Sec tRNA
(i6A) to determine what effect this would have on prostate
tumorigenesis in transgenic mice expressing the SV40 large-
T and small-t oncogenes (C3(1)/Tag) in their prostates.12
Interestingly, the bigenic mice exhibited accelerated tumor
development, suggesting that one or more SPs were
involved in suppressing tumor evolution.
There has been considerable speculation and circum-
stantial evidence supporting a role for oxidative stress in
human prostate cancer.13,14 Although much work impli-
cating ROS has been performed on human prostate cancer
cell lines in vitro, as well as in xenografted and transgenic
mice,15,16 there is a paucity of direct evidence in either
humans or mice demonstrating that oxidative stress plays a
tumor-initiating role in this disease.
The targeted removal of Trsp in all tissues was embryonic
lethal, indicating that there are one or more SPs that are
essential for normal development.17 Hence, investigation of
SP deﬁciency in vivo has required a conditional (Cre-LoxP)
mutagenesis approach. Studying the consequences of tissue-
speciﬁc Trsp gene loss allows insight into the role of the SP
family in any given organ or cell type. Thus, to determine
whether prostate-speciﬁc deletion of SP would have any
effect on the normal murine prostate, we interbred mice
carrying loxP-ﬂanked (ﬂoxed) Trsp alleles (Trspﬂ/ﬂ)17 with
mice expressing a prostate-speciﬁc Cre transgene.18 Our
results demonstrate that Trsp deletion in the prostatic
epithelium leads to the rapid development of prostatic
intraepithelial neoplasia (PIN) lesions.
It should be noted that our ﬁndings neither contradict nor
are made irrelevant by the negative results of the SELECT
trial (Selenium and Vitamin E Cancer Prevention Trial).19872This trial, which enrolled men with normal to high Se
blood levels at entry, was intended to evaluate whether di-
etary Se (with and without vitamin E) supplementation
would decrease the risk of prostate cancer development. Its
purpose was not to demonstrate whether SP levels were
relevant to human prostate tumorigenesis. Although gener-
alized SP deﬁciency leads to the rapid development of PIN
lesions in mice, in humans, isolated SP deﬁciencies would
likely exert more subtle effects. It is conceivable nonethe-
less, and in view of the evidence that oxidative stress may
be important to the pathogenesis of the human dis-
ease,13,14,20 that our Trsp model represents an abbreviated
scenario of a process that might ordinarily be played out
over many decades in humans.
Materials and Methods
Generation of Mice
Trspﬂ/ﬂ mice17 were interbred with a PB*Cre4 mouse line
expressing Cre recombinase under the control of a com-
posite promoter, ARR2PB, a derivative of the rat prostate-
speciﬁc probasin (PB) promoter that is fused to two
androgen response elements (ARR2).18 Cre expression in
the PB*Cre4 line occurs postnatally, under androgen con-
trol, and hence allows excisions of ﬂoxed genes in the
prostatic epithelium. Each line was backcrossed for nZ 10
generations onto the C57BL/6J background. Mice were
housed in a viral antibodyefree barrier facility in accor-
dance with Canadian Council on Animal Care guidelines,
and with ethical approval by the University of Calgary
Animal Care Committee.
Genotyping
Tail-tip clippings from pups were taken immediately post-
weaning and processed for genotyping for both the Trspﬂ/ﬂ
and the Cre transgene as previously described.17,18
Histology and Immunohistochemistry
The dissected lower urogenital tracts of the mice were ﬁxed
in 10% formaldehyde, embedded in parafﬁn, and sectioned at
5 mm. Sections were deparafﬁnized with xylene and graded
alcohols, and sections were stained with H&E for micro-
scopy. For immunohistochemistry, sections were deparafﬁ-
nized as above, and antigen retrieval was performed using 10
mmol/L sodium citrate (pH 6.0). For cryosections, animals
were perfused with 4% paraformaldehyde after a lethal dose
of ketamineexylazine, and dissected lower urogenital tracts
were embedded in optimal cutting temperature compound
and cryosectioned at 10 mm. Antibodies used were against
Sep15, GPx4, dTR1 (Epitomics, Burlingame, CA), Ki-67
(Novocastra, Newcastle Upon Tyne, UK) pAKT, phospho-
p42/44 mitogen-activated protein kinase (MAPK), phospho-
p38 MAPK, and pS6 (Cell Signaling Technology, Danvers,ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Reduced expression of selenoproteins in prostates of
PBCre4;Trspﬂ/ﬂ mice. Tissue sections of prostates from 6- to 10-week-old
Trspﬂ/ﬂ and PBCre4Trspﬂ/ﬂ mice were immunostained with antibodies
against GPx4 and Sep15. PBCre4;Trspﬂ/ﬂ prostates show lack of detectable
expression of these selenoproteins in the luminal epithelium (C, D, G, and
H), as a consequence of Trsp excision. Staining results were replicated on
prostates from three to six experimental and control mice. Boxed areas in
A, C, E, and G correspond to higher-magniﬁcation images in B, D, F, and H,
respectively. Scale bars: 200 mm (A, C, E, and G); 20 mm (B, D, F, and H).
Table 1 Summary of Immunostaining of PBCre4;Trspﬂ/ﬂ
Prostates
Target Trspﬂ/ﬂ PBCRe4;Trspﬂ/ﬂ
Sep15 þ 
GPx1 þ 
GPx4 þ Decreased
TR1 þ Decreased
Ki-67 Minimal þ
TUNEL staining Minimal þ
p42/p44 MAPK  þ
pAKT  þ
pS6  þ
p38MAPK  þ
NF-kB  
HIF1a  
Nitrotyrosine þ þ
MDA Minimal þ
4-HNE Minimal þ
Prostates of 6- to 29-week-old PBCre4;Trspﬂ/ﬂ and Trspﬂ/ﬂ controls were
immunostained. Minimal denotes a modest level of positive staining but at
levels lower than in the other groups.
þ, positive staining; , lack of staining.
PIN in Trsp-Deﬁcient Murine ProstateMA), nitrotyrosine (Millipore, Billerica, MA), malondial-
dehyde (MDA; Abcam, Cambridge, UK), and 4-
hydroxynonenal (4-HNE; Millipore); and either the mouse
IgG Vectastain Elite ABC kit or the rabbit IgG ABC kit from
Vector Laboratories (Burlingame, CA) were used as sec-
ondary reagents. Color development was performed with
DAB substrate (Sigma-Aldrich, St. Louis, MO), and sections
were counterstained with hematoxylin. PAS staining was
performed at the Calgary Laboratory Services pathology
laboratory according to standard protocols.
Quantiﬁcation of Proliferation
The proliferation index was determined as the percentage of
Ki67-positive cells over total cells counted.At least 1000 cells
per animal were counted over ﬁve different ﬁelds of view, and
four mice were included per group. Student’s t-test (two-
tailed, unequal variance) was used for statistical analyses.The American Journal of Pathology - ajp.amjpathol.orgApoptosis Assay
The dissected lower urogenital tracts of the mice were ﬁxed
in 10% formaldehyde, embedded in parafﬁn, and sectioned
at 5 mm. Sections were deparafﬁnized with xylene and
graded alcohols before the TUNEL assay, which was per-
formed with the ApopTag Peroxidase in Situ Apoptosis
Detection kit according to the manufacturer’s instructions
(Chemicon International, Temecula, CA).
Results
Deleting the Trsp Gene Leads to Loss of SPs in the
Prostatic Epithelium
It has been previously shown that Trsp knockout mice are
embryonic lethal21; therefore, to get prostate-speciﬁc dele-
tion of Trsp, we crossed mice with ﬂoxed Trsp alleles to a
mouse line (PBCre4) expressing Cre recombinase under
the control of a composite promoter, ARR2PB.18 Using
immunohistochemistry, we observed that prostate-speciﬁc
excision of the Trsp gene led to a loss of GPx4 (Figure 1,
C and D) and Sep15 (Figure 1, G and H) in the prostatic
epithelium (controls are shown in Figure 1, A, B, E, and F).
The reduced selenoprotein expression was detectable as
early as 6 weeks of age (Figure 1). Loss of GPx4 was less
dramatic than that of Sep15, perhaps owing to some residual
protein being recognized by the anti-GPx4 antibody despite
the premature translational termination that is predicted to
occur in the absence of Sec tRNA, or alternatively, to a
cross-reactive epitope present in the prostatic epithelium.
Similarly, reduction of GPx1 was more dramatic than that of
the TR1 selenoprotein (Table 1). Taken together, the results
thus showed that Cre recombinaseedriven excision of the873
Luchman et alTrsp gene inhibited the expression of various SPs in the
prostatic epithelium.
Lack of SP Expression in Prostatic Epithelium Leads to
PIN and Microinvasive Adenocarcinoma
Decreased levels of SPs induced by the transgenic expression
of a mutant Sec tRNA (i6A) in the prostate were previously
linked to accelerated development of prostate cancer in
C3(1)/Tag mice.12 Herein, we investigated whether Trsp
excision in the prostatic epithelium would lead to abnormal
morphology indicative of early-stage prostate cancer. Indeed,
we found that PBCre4;Trspﬂ/ﬂ mice demonstrated abnormal
morphology and PIN lesions in all three lobes of the prostate
as early as 6 weeks of age (Figure 2, AeD). Abnormal his-
topathology was observed with cellular disorganization,
cellular and nuclear enlargement and atypia, and basement
membrane thickening with cellular microinvasion into the
stroma. Dramatic hyperchromasia and mitosis, and cell
stratiﬁcation were observed (Supplemental Figure S1A). As
the mice aged, the phenotype became more pronounced such874that high-grade PIN lesions and more extreme examples of the
above phenotypeswere observed by 24weeks of age (Figure 2,
EeH, and Supplemental Figure S1B). Control animals at this
stage exhibited no evidence of any abnormal histopathology
(Supplemental Figure S1, CeF). Thus, PBCre4;Trspﬂ/ﬂ mice
between 6 and 29 weeks displayed all of the characteristic
histopathological features of prostate cancer with 100% pene-
trance, including high-grade PIN lesions and microinvasive
adenocarcinoma, in contrast to control Trspﬂ/ﬂ animals, which
exhibited neither of these features. There was no additional
progression past high-grade lesions and invasive adenocarci-
noma into metastasis when animals were aged to 30 weeks. In
summary, these results indicated that Trsp excision, and hence,
lack of SPs in the prostatic epithelium, was sufﬁcient to lead to
high-grade PIN lesions and microinvasive carcinoma.
Increased Proliferation and Apoptosis in the Prostates
of PBCre4;Trspﬂ/ﬂ Mice
Further signs of tumorigenesis were conﬁrmed by PAS
staining of PBCre4;Trspﬂ/ﬂ prostates, which showed thinningFigure 2 Characteristic features of tumorigenesis in
prostates of PBCre4;Trspﬂ/ﬂ mice. Abnormal morphology and
PIN lesions observed in all three lobes of the prostate at 6
weeks (AeD). Abnormal histopathology including cellular
disorganization, cellular and nuclear enlargement and atypia
(blue arrowheads and square brackets), and basement
membrane thickening with cellular microinvasion into the
stroma (black arrows). The phenotype was more pronounced
in older mice (shown at 24 weeks), with high-grade PIN
lesions and more extreme examples of the above phenotypes
(EeH). F and H: Regions showing cellular and nuclear disor-
ganization, enlargement and atypia, microinvasion (blue ar-
rows and square brackets), and basement membrane
thickening (black arrows). Penetrance was 100% with ani-
mals in all age groups displaying PIN lesions. Representative
images of prostates from ﬁve to eight mice from each group
and time point are shown. F and H are higher magniﬁcations
of E and G, respectively. Scale bars: 200 mm (A); 50 mm
(BeD); 100 mm (E and G); 20 mm (F and H). An, anterior lobe;
Do, dorsal lobe.
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tubules and microinvasion of luminal epithelial cells into the
stroma (Figure 3, A and B). The Ki-67 marker was used to
assess proliferation in the prostatic epithelium of
PBCre4;Trspﬂ/ﬂ mice. Luminal epithelial cells were found to
be positive for Ki67 in the prostates of the Cre-positive ani-
mals (Figure 3D). This was observed in prostates of young
adult mice at 6 weeks of age as well as in the luminal
epithelium and PIN lesions of older mice, at a time when the
prostate is fully developed and cell division is minimal, asFigure 3 Microinvasive carcinoma, increased proliferation, and
apoptosis in prostates of PBCre4;Trspﬂ/ﬂ mice. Positive PAS staining in
PBCre4;Trspﬂ/ﬂ prostates (A). B is a higher magniﬁcation of the boxed
region in A. Thinning and disruption of basement membrane (A, black
arrows) and microinvasion of luminal epithelium cells in stroma (A and B,
green arrowheads) were observed. Compared to prostates of control mice
(C), increased numbers of luminal epithelial cells positive for Ki-67 were
observed in PBCre4;Trspﬂ/ﬂ (D, red arrowheads) and conﬁrmed through
quantiﬁcation (E). P < 0.0002 versus control Trspﬂ/ﬂ mice. Compared to
Trspﬂ/ﬂ mice (F), increased TUNEL-positive cells (G, black arrowheads)
were also observed in the prostates of PBCre4;Trspﬂ/ﬂ mice. PAS staining
was performed on 25-week-old mice; Ki-67 and TUNEL were performed on 6-
week-old mice. A minimum of three to ﬁve animals were used per condi-
tion. Scale bars: 100 mm (A, C, D, F, and G); 20 mm (B).
The American Journal of Pathology - ajp.amjpathol.orgseen in the prostates of control Trspﬂ/ﬂ mice (Figure 3C).
Quantiﬁcation of the Ki-67 in the prostates of 6-week-old
PBCre4;Trspﬂ/ﬂ demonstrated a striking increase in the
numbers of Ki67-positive cells (Figure 3E).
The TUNEL assay, to identify the presence of apoptotic
cells in the prostatic epithelium of PBCre4;Trspﬂ/ﬂ mice,
revealed increased numbers of apoptotic luminal epithelial
cells (Figure 3G) compared to control prostates (Figure 3F).
SP Loss in the Prostate Leads to Activation of
Pro-Oncogenic Pathways and Oxidative Stress
To further investigate the mechanisms through which SP
loss resulted in PIN development, we performed immuno-
histochemistry on the prostate tissue of mice using a series
of antibodies against various effectors of pro-oncogenic
pathways. We found up-regulation of p42/p44 MAPK
(Figure 4, A and B) and phospho-S6 (Figure 4, C and D),
consistent with activation of both the MAPK and PI3K
pathways (Table 1). Interestingly, activated p42/p44 MAPK
seemed to be present primarily in cells on the outermost
regions of the tubules with PIN lesions (Figure 4B), whereas
pS6 levels tended to be increased in cells within the tubule
lumens (Figure 4D).
Because decreased Se and SP levels have been associated
with increased oxidative stress,22,23 we investigated whether
Trsp excision would be accompanied by markers of
oxidative stress. Indeed, we found that PBCre4;Trspﬂ/ﬂ
prostates displayed increased p38 MAPK staining (Figure 4,
E and F). Although we were not able to discern differences
in NF-kB, hypoxia-inducible factor-1a (HIF-1a), and
nitrotyrosine, we did ﬁnd striking increases in the levels of
the lipid peroxidation markers MDA (Figure 4, G and H)
and 4-HNE (Figure 4, I and J). The latter results were
consistent with Trsp loss being accompanied by oxidative
stresseinduced lipid peroxidation.Discussion
Our study demonstrates that interbreeding Trspﬂ/ﬂ and
PB*Cre4 mice, not only effectively reduced prostatic
epithelial expression of SPs, but also led to development of
PIN lesions and early carcinoma in mice within the ﬁrst 2
months of age. We speculate that increased oxidative stress,
for example, due to reduced levels of SPs such as GPx-1, -4,
and Sep15, might play a role in this process, perhaps via the
triggering of pro-oncogenic pathways. Indeed, dramatically
lowered expression of speciﬁc SPs in the prostates of the
PBCre4;Trspﬂ/ﬂ mice was associated with up-regulation of
the cell proliferation indicator, Ki-67, and markers of pro-
oncogenic pathway activation, including pS6 and pMAPK.
Furthermore, there was increased apoptosis in the prostates of
the experimental animals consistent with an increased rate of
cell turnover, likely exacerbated by the combination of ROS-
mediated cell damage and nutrient deprivation affecting cells875
Figure 4 Activation of pro-oncogenic and oxidative stress signals. Up-
regulation of phospho-p42/p44 MAPK (p42/p44 ERK) (B), and phospho-S6
(pS6) (D) signals were seen in prostates of PBCre4;Trspﬂ/ﬂ mice, but not in
controls (A and C). Increases in the levels of phospho-p38MAPK (F) and of
the lipid peroxidation markers malondialdehyde (H) and 4-hydroxynonenal
(J) were also observed in the PBCre4;Trspﬂ/ﬂ prostatic epithelium compared
to controls (E, G, and I). Prostates from 6- to 29-week-old mice were used;
representative immunostaining is shown for 10-week-old mice (p38MAPK)
and 24-week-old mice (MDA and 4-HNE) with three to ﬁve animals used per
condition. Scale bars: 100 mm (AeD and GeJ); 200 mm (E and F).
Luchman et althat were accumulating within the avascular intratubular
compartment. Although we found increased staining in
phosphorylated p38 MAPK, a further indication of oxidative
stress in the PBCre4;Trspﬂ/ﬂ prostates, we were unable to
detect differences in the levels or localization of other protein
sensors commonly associated with oxidative stress such as
NF-kB and HIF-1a. This may be due to these proteins, and
especially HIF-1a, being labile and hence undetectable in our
processed specimens.
In support of oxidative stress being present in the prostates
of Trsp-deﬁcient animals, we found an up-regulation of the
lipid peroxidation markers, MDA and 4-HNE, indicative of
oxidative stress within the prostatic epithelium. GPx4 acts,
not only on H2O2, but also on soluble fatty acid hydroper-
oxides (reviewed in Brigelius-Flohe24), and is the primary
antioxidant enzyme capable of directly reducing lipid hy-
droperoxides within all cellular membranes (reviewed in
Brigelius-Flohe24). The ability of GPx4 to act on lipid876hydroperoxides plays a major role in cytoprotection against
ROS. In keeping with this idea, GPx4-overexpressing mice
were found to be more resistant to oxidative insults (reviewed
in Brigelius-Flohe24 and Liang et al25). We found decreased
levels of GPx4 in the prostates of PBCre4;Trspﬂ/ﬂ mice,
suggesting that deﬁciency of this SP accounted for the
increased 4-HNE and MDA immunostaining we observed in
the PIN lesions.
The widespread nature of the lesions throughout the lobes
of the prostate and their occurrence in all Trsp-deﬁcient mice
argue against a stochastic process such as might be expected
if oxidative stress were randomly inducing DNA mutations
in key growth control genes. Instead, the histopathology was
consistent with a ﬁeld effect, whereby large numbers of
progenitors were being stimulated to turn over. This would
be in keeping with the ability of ROS to stimulate various
pro-growth effectors,26,27 such as the increased levels of
phospho-p42/44 MAPK, phospho-p38 MAPK p42/p44
MAPK, p38 MAPK, and phospho-S6 that we observed in
the PIN lesions. It is feasible, once a generalized hyperplasia
is established, that ROS-induced mutations, cytogenetic
aberrations, or epigenetic alteration could act to promote the
selection of clones with increased malignancy. This could
have accounted for the increased levels of dysplasia and
microinvasion we observed in the Trsp-deﬁcient prostates of
older mice.
Normal cellular SP activity is thought to be protective
against tumorigenesis.2 Although the function of some SPs
is still unknown, SPs whose deﬁciency may predispose to an
increased cancer risk include members of the GPx family,
Sep15, and the thioredoxin reductases.28 The loss of Trsp
would lead to deﬁciencies in all SPs expressed in mouse
prostate. Thus, in addition to GPx4, there could be other SPs
whose losses act to promote PIN development, and it is
conceivable that PIN lesions result from a speciﬁc combi-
nation of SP deﬁciencies. However, in view of the unique
properties of the GPx4 isoforms that provide a defense
against lipid peroxidation events, we hypothesize that
reduced levels of GPx4 render it a candidate, accounting for
PIN lesions developing in Trsp-deﬁcient mice. Furthermore,
deletion of Gpx4 has been shown to phenocopy the effects
of Trsp deletion in other cell types (eg, neuronal cells).29 It
could thus be speculated that GPx4 might be one of the SPs
whose deﬁciency promotes PIN development in Trsp-deﬁ-
cient prostates.
It is intriguing that many lines of evidence have pointed
to a role for oxidative stress in the pathogenesis of human
prostate cancer13,14 as well as in the progression to androgen
independence.30 Our results raise the possibility that
oxidative stress may have a direct oncogenic role in the
pathogenesis of PINs, and suggest that severe Se deﬁciency,
or gene polymorphisms that decrease the activity of SPs,
might predispose humans to prostate cancer. Indeed, gene
polymorphisms or decreased expression of speciﬁc SPs
have already been implicated as potential etiological factors
in human prostate cancer.31e36ajp.amjpathol.org - The American Journal of Pathology
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